Importantly, we also provide a strategy to augment the therapeutic profile of the current frontline treatment for human obesity, GLP-1R agonists, via combination with 5-HT2CR agonists. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.